CanBas Co., Ltd. (JP:4575)
:4575
4575 Stock Chart & Stats
¥787.00
-¥23.00(-2.48%)
At close: 4:00 PM EST
¥787.00
-¥23.00(-2.48%)
Day’s Range― - ―
52-Week Range¥685.00 - ¥1,558.00
Previous CloseN/A
Volume347.00K
Average Volume (3M)268.48K
Market Cap
¥14.73B
Enterprise Value¥12.52B
Total Cash (Recent Filing)¥2.83B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.04
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,713,655
10 Day Avg. Volume208,910
30 Day Avg. Volume268,476
Financial Highlights & Ratios
PEG Ratio1.96
Price to Book (P/B)7.69
Price to Sales (P/S)0.00
P/FCF Ratio-29.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stronger Balance SheetZero reported debt and materially higher equity materially reduce leverage risk and improve financial flexibility. This strengthens the company's ability to fund clinical programs, negotiate partner deals, and survive development cycles without immediate repayment pressure, a durable improvement for an R&D biotech.
Partnering/licensing Business ModelA partnering-and-licensing model is well aligned with pre-commercial oncology R&D: milestone and royalty streams can monetize assets without full commercialization costs. Durable structural benefit: successful partner deals can de-risk programs, provide non-dilutive funding and scale commercialization infrastructure.
Improving Cash Burn TrendA material moderation in operating cash outflows and narrower net losses indicate improving cost discipline or funding mix. If sustained, this reduces near-term financing needs, lengthens runway for clinical programs, and increases the probability of reaching de-risking milestones with fewer dilutive raises.
Bears Say
Persistent LossesOngoing operating and net losses with negligible revenue means the company cannot self-fund development. Over the medium term this raises execution risk: failed trials or delayed milestones would quickly force external financing, slowing program progress and diluting shareholders.
Chronic Negative Cash FlowPersistently negative operating and free cash flow creates structural reliance on equity or partner financing. This elevates dilution and funding-risk for multi-year oncology programs, and can constrain R&D sequencing, making long-term progress contingent on successful external financing or partnership outcomes.
Capital Returns WeakDeeply negative return on equity signifies capital destruction rather than creation. For investors and potential partners this signals that existing programs have not yet translated into value, making future fundraising harder and potentially more dilutive unless pipeline milestones materially de-risk prospects.
4575 FAQ
What was CanBas Co., Ltd.’s price range in the past 12 months?
CanBas Co., Ltd. lowest stock price was ¥685.00 and its highest was ¥1558.00 in the past 12 months.
What is CanBas Co., Ltd.’s market cap?
CanBas Co., Ltd.’s market cap is ¥14.73B.
When is CanBas Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CanBas Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is CanBas Co., Ltd. overvalued?
According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued.
Does CanBas Co., Ltd. pay dividends?
CanBas Co., Ltd. does not currently pay dividends.
What is CanBas Co., Ltd.’s EPS estimate?
CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CanBas Co., Ltd. have?
CanBas Co., Ltd. has 19,713,655 shares outstanding.
What happened to CanBas Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CanBas Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4575
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CanBas Co., Ltd.
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―